Exhibit 10.1

 

[g256551kmi001.jpg]

--------------------------------------------------------------------------------

[g256551kmi002.jpg]

--------------------------------------------------------------------------------

[g256551kmi003.jpg]

--------------------------------------------------------------------------------

[g256551kmi004.jpg]

--------------------------------------------------------------------------------

[g256551kmi005.jpg]

--------------------------------------------------------------------------------

[g256551kmi006.jpg]

--------------------------------------------------------------------------------

[g256551kmi007.jpg]

--------------------------------------------------------------------------------

[g256551kmi008.jpg]

--------------------------------------------------------------------------------

[g256551kmi009.jpg]

--------------------------------------------------------------------------------

[g256551kmi010.jpg]

--------------------------------------------------------------------------------

[g256551kmi011.jpg]

--------------------------------------------------------------------------------

[g256551kmi012.jpg]

--------------------------------------------------------------------------------

[g256551kmi013.jpg]

--------------------------------------------------------------------------------

 

AMENDMENT to TECHNICAL SERVICES AGREEMENT

 

This AMENDMENT to TECHNICAL SERVICES AGREEMENT (this “Amendment”), dated as of
October 27, 2011, is between United Therapeutics Corporation, located at 1040
Spring St., Silver Spring, MD 20910, (“United Therapeutics”) and Kurzweil
Technologies, Inc., (“KTI”).  Party shall mean United Therapeutics or KTI as the
context dictates, and “Parties” shall mean United Therapeutics and KTI.

 

WHEREAS, United Therapeutics and KTI are parties to that certain Technical
Services Agreement dated May 15, 2007 (the “TSA”);

 

WHEREAS, United Therapeutics and KTI wish to amend the TSA to align with changed
circumstances.

 

NOW, THEREFORE, in consideration of the terms and conditions specified herein
and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Parties hereby agree as follows:

 

1.               AMENDMENTS.  The TSA is hereby amended, with effect from
January 1, 2012, as follows:

 

1.1.           In Section 2(a), each instance of the number “$12,000” is
replaced with “$6,000.”

 

1.2.           In Section 2(a), the umber “$144,000” is replaced with “$72,000.”

 

2.               COUNTERPARTS. This Amendment may be executed in counterparts
and all such counterparts taken together shall be deemed to constitute one and
the same instrument. If this Amendment is executed in counterparts, no signatory
hereto will be bound until both parties named below have duly executed a
counterpart of this Amendment.

 

3.               EFFECT OF AMENDMENT.  Except as specifically amended hereby,
all other terms and conditions of the TSA remain in effect. To the extent that
any of the terms in the TSA are inconsistent with the terms of this Amendment,
the terms of this Amendment shall control.

 

IN WITNESS WHEREOF, the United Therapeutics and KTI, intending to be legally
bound have executed this Amendment as of the date first set forth above by their
respective duly authorized representatives.

 

Kurzweil Technologies Inc.

 

United Therapeutics Corporation

 

 

 

/s/ Raymond Kurzweil

 

/s/ Martine Rothblatt

Raymond Kurzweil, CEO

 

Martine Rothblatt, CEO

 

--------------------------------------------------------------------------------